Pfizer, Hydra strike $195M pain pact

Cambridge, MA-based Hydra Biosciences has struck a deal with Pfizer Global Research & Development to collaborate on new pain therapies. Hydra stands to gain up to $195 million in up front and milestone payments--there's no breakdown on the numbers--for the first product developed from the Transient Receptor Potential channel family. Pfizer will fund all research and development work and gains exclusive commercialization rights to any product developed in the collaboration.

"We have distinct capabilities in rapid ion channel assay development and high throughput screening, we employ the 'gold standard' in characterizing all viable compounds, and we are building a particular expertise in chemistry," said Hydra CEO Russell Herndon. "Driving this franchise is a deep pipeline of programs advancing through development in a variety of pain indications, renal disease, pulmonary dysfunction, and hypertension."

- here's the release on the deal

Related Articles:
Pfizer's Lyrica approved for fibromyalgia. Report
Renovis gains milestone payments from Pfizer. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.